Lilly Reports Strong First-Quarter 20... (The company recognized a charge of $87.0...)

Lilly Reports Strong First-Quarter 2009 Results

Date:4/20/2009

The company recognized a charge of $87.0 million, or $.05 per share, for acquired in-process research and development associated with the BioMS in-licensing arrangement.

The company recognized a discrete income tax benefit of $210.3 million as a result of the resolution of a substantial portion of the IRS audit of its federal income tax returns for years 2001 through 2004, which increased earnings per share by $.19.

Assuming the ImClone acquisition was completed on January 1, 2008, the pro forma impact of the acquisition would have decreased net income by $.04 per share in the first quarter of 2008.

                                                 First Quarter
                                                 -------------
                                                2009      2008       % Growth
                                                ----      ----       --------
    Earnings per share (reported)              $1.20      $.97           24%
      Asset impairments, restructuring and
       other special charges                       -       .09
      In-process research and development
       charge associated with the BioMS
       in-licensing                                -       .05
      Benefit from resolution of IRS audit         -      (.19)
      Pro forma as if the ImClone acquisition
       was completed on January 1, 2008            -      (.04)
                                                ----      ----
      Earnings per share (pro forma non-GAAP)  $1.20      $.88           36%
                                                ----      ----

First-Quarter Reported Results

In the first quarter, worldwide total revenue was $5.047 billion, an increase of 5 percent compared with the first quarter of 2008. This 5 percent revenue growth was comprised of a 7 percent increase due to high
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Lillys CEO Calls for Reform of Nations Drug Safety System
6. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
7. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
8. Lilly Delivers Strong Third-Quarter Results
9. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
10. Eli Lilly and Company Aids California Recovery Effort
11. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients

Post Your Comments:

Lilly Reports Strong First-Quarter 20...(The company recognized a charge of $87.0...),Health